Strs Ohio raised its stake in Celldex Therapeutics, Inc. (NASDAQ:CLDX – Free Report) by 8.3% in the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 6,500 shares of the biopharmaceutical company’s stock after acquiring an additional 500 shares during the period. Strs Ohio’s holdings in Celldex Therapeutics were worth $220,000 as of its most recent filing with the Securities and Exchange Commission (SEC).
Several other large investors also recently bought and sold shares of the stock. Arizona State Retirement System boosted its stake in Celldex Therapeutics by 3.4% in the first quarter. Arizona State Retirement System now owns 10,917 shares of the biopharmaceutical company’s stock valued at $393,000 after acquiring an additional 359 shares in the last quarter. Legal & General Group Plc raised its holdings in shares of Celldex Therapeutics by 2.1% in the fourth quarter. Legal & General Group Plc now owns 17,215 shares of the biopharmaceutical company’s stock valued at $767,000 after buying an additional 360 shares during the last quarter. Silverarc Capital Management LLC raised its holdings in shares of Celldex Therapeutics by 0.9% in the first quarter. Silverarc Capital Management LLC now owns 45,538 shares of the biopharmaceutical company’s stock valued at $256,000 after buying an additional 406 shares during the last quarter. First Trust Advisors LP raised its holdings in shares of Celldex Therapeutics by 4.4% in the third quarter. First Trust Advisors LP now owns 10,399 shares of the biopharmaceutical company’s stock valued at $292,000 after buying an additional 440 shares during the last quarter. Finally, Allspring Global Investments Holdings LLC raised its holdings in shares of Celldex Therapeutics by 77.5% in the second quarter. Allspring Global Investments Holdings LLC now owns 1,136 shares of the biopharmaceutical company’s stock valued at $39,000 after buying an additional 496 shares during the last quarter.
Analyst Upgrades and Downgrades
CLDX has been the subject of a number of research reports. Wells Fargo & Company initiated coverage on shares of Celldex Therapeutics in a report on Tuesday, August 22nd. They issued an “underweight” rating for the company. Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $54.00 target price on shares of Celldex Therapeutics in a report on Thursday, October 12th. Finally, HC Wainwright reissued a “buy” rating and set a $73.00 price target on shares of Celldex Therapeutics in a report on Thursday, August 10th. Two investment analysts have rated the stock with a sell rating and three have given a buy rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Hold” and an average target price of $63.33.
Celldex Therapeutics Trading Up 0.2 %
Shares of CLDX stock opened at $23.57 on Thursday. The company has a market cap of $1.11 billion, a price-to-earnings ratio of -9.82 and a beta of 2.13. The stock has a 50 day simple moving average of $26.60 and a 200-day simple moving average of $31.37. Celldex Therapeutics, Inc. has a 12-month low of $22.11 and a 12-month high of $48.40.
Celldex Therapeutics (NASDAQ:CLDX – Get Free Report) last issued its earnings results on Tuesday, August 8th. The biopharmaceutical company reported ($0.65) earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of ($0.65). The business had revenue of $0.27 million during the quarter, compared to the consensus estimate of $0.67 million. Celldex Therapeutics had a negative return on equity of 36.15% and a negative net margin of 3,475.70%. On average, equities analysts forecast that Celldex Therapeutics, Inc. will post -2.64 earnings per share for the current fiscal year.
Celldex Therapeutics Profile
Celldex Therapeutics, Inc, a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory diseases and various forms of cancer. The company's clinical development programs CDX-0159, a Phase II monoclonal antibody that binds the receptor tyrosine kinase KIT and inhibits its activity; CDX-1140, a human agonist monoclonal antibody targeted to CD40, a key activator of immune response, which is found on dendritic cells, macrophages, and B cells, as well as is expressed on various cancer cells; and CDX-527, a bispecific antibody, which uses the company's proprietary active anti-PD-L1 and CD27 human antibodies to couple CD27 costimulation with blockade of the PD-L1/PD-1 pathway to help prime and activate anti-tumor T cell responses through CD27 costimulation.
Featured Articles
- Five stocks we like better than Celldex Therapeutics
- CD Calculator: Certificate of Deposit Calculator
- First Solar, an affordable, high-quality green investment
- How Can Investors Benefit From After-Hours Trading
- 5 Dow stocks to track during the market correction
- How to Invest in Esports
- Lean on these stocks during GDP expansion
Want to see what other hedge funds are holding CLDX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Celldex Therapeutics, Inc. (NASDAQ:CLDX – Free Report).
Receive News & Ratings for Celldex Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celldex Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
